These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 27854302)

  • 1. Severe Cutaneous Adverse Reactions: The Pharmacogenomics from Research to Clinical Implementation.
    Su SC; Hung SI; Fan WL; Dao RL; Chung WH
    Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27854302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenomics of severe cutaneous adverse reactions and drug-induced liver injury.
    Kaniwa N; Saito Y
    J Hum Genet; 2013 Jun; 58(6):317-26. PubMed ID: 23635947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenetic markers of severe cutaneous adverse drug reactions.
    Borroni RG
    G Ital Dermatol Venereol; 2014 Apr; 149(2):219-26. PubMed ID: 24819643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetics and the potential for predictive tests in adverse drug reactions.
    Pirmohamed M
    Chem Immunol Allergy; 2012; 97():18-31. PubMed ID: 22613851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug-Induced Skin Adverse Reactions: The Role of Pharmacogenomics in Their Prevention.
    Gerogianni K; Tsezou A; Dimas K
    Mol Diagn Ther; 2018 Jun; 22(3):297-314. PubMed ID: 29564734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HLA alleles and drug hypersensitivity reactions.
    Profaizer T; Eckels D
    Int J Immunogenet; 2012 Apr; 39(2):99-105. PubMed ID: 22136512
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing.
    Hershfield MS; Callaghan JT; Tassaneeyakul W; Mushiroda T; Thorn CF; Klein TE; Lee MT
    Clin Pharmacol Ther; 2013 Feb; 93(2):153-8. PubMed ID: 23232549
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HLA-B*5801: utility and cost-effectiveness in the Asia-Pacific Region.
    Yeo SI
    Int J Rheum Dis; 2013 Jun; 16(3):254-7. PubMed ID: 23981744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The associations between idiosyncratic adverse drug reactions and HLA alleles and their underlying mechanism].
    Wang Q; Mei H; Zhang YL; Pan XC; Tan W; Chao L
    Yao Xue Xue Bao; 2013 Jun; 48(6):799-808. PubMed ID: 23984511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HLA-B allele associations with certain drugs are not confirmed in Japanese patients with severe cutaneous drug reactions.
    Kano Y; Hirahara K; Asano Y; Shiohara T
    Acta Derm Venereol; 2008; 88(6):616-8. PubMed ID: 19002350
    [No Abstract]   [Full Text] [Related]  

  • 11. Prevention of severe cutaneous adverse drug reactions: the emerging value of pharmacogenetic screening.
    Fernando SL; Broadfoot AJ
    CMAJ; 2010 Mar; 182(5):476-80. PubMed ID: 19933789
    [No Abstract]   [Full Text] [Related]  

  • 12. Human leukocyte antigens and drug hypersensitivity.
    Chung WH; Hung SI; Chen YT
    Curr Opin Allergy Clin Immunol; 2007 Aug; 7(4):317-23. PubMed ID: 17620823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Exploratory study on biomarkers associated with severe cutaneous adverse reactions].
    Kaniwa N
    Yakugaku Zasshi; 2011 Feb; 131(2):255-61. PubMed ID: 21297371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human leukocyte antigen-B*58:01 allele in a familial case of Stevens-Johnson syndrome induced by allopurinol.
    Caldarola G; Sollena P; Peris K; De Simone C
    J Dermatol; 2015 Jul; 42(7):753-4. PubMed ID: 25899558
    [No Abstract]   [Full Text] [Related]  

  • 15. Genotyping for severe drug hypersensitivity.
    Karlin E; Phillips E
    Curr Allergy Asthma Rep; 2014 Mar; 14(3):418. PubMed ID: 24429903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HLA-B58 can help the clinical decision on starting allopurinol in patients with chronic renal insufficiency.
    Jung JW; Song WJ; Kim YS; Joo KW; Lee KW; Kim SH; Park HW; Chang YS; Cho SH; Min KU; Kang HR
    Nephrol Dial Transplant; 2011 Nov; 26(11):3567-72. PubMed ID: 21393610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Personalized Medicine Approach to Guide Allopurinol Use and Prevent Serious Adverse Events: Ethnicity Is Not a Proxy for Genetics.
    Ikediobi O
    Clin Pharmacol Ther; 2021 Oct; 110(4):852-854. PubMed ID: 33330976
    [No Abstract]   [Full Text] [Related]  

  • 18. Allopurinol pharmacogenetics: assessment of potential clinical usefulness.
    Zineh I; Mummaneni P; Lyndly J; Amur S; La Grenade LA; Chang SH; Rogers H; Pacanowski MA
    Pharmacogenomics; 2011 Dec; 12(12):1741-9. PubMed ID: 22118056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Positive and negative associations of HLA class I alleles with allopurinol-induced SCARs in Koreans.
    Kang HR; Jee YK; Kim YS; Lee CH; Jung JW; Kim SH; Park HW; Chang YS; Jang IJ; Cho SH; Min KU; Kim SH; Lee KW;
    Pharmacogenet Genomics; 2011 May; 21(5):303-7. PubMed ID: 21301380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HLA-B*58:01 is strongly associated with allopurinol-induced severe cutaneous adverse reactions in Han Chinese patients: a multicentre retrospective case-control clinical study.
    Cheng L; Xiong Y; Qin CZ; Zhang W; Chen XP; Li J; Zhou HH
    Br J Dermatol; 2015 Aug; 173(2):555-8. PubMed ID: 26104483
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.